Scancell, a British pharmaceutical firm, has been awarded a European patent for its DNA ImmunoBody scientific platform, the Telegraph reported.
This technology is vital to its pipeline of potential cancer vaccines, with scientists at the company hopeful that their approach to treating the disease could lead to a permanent cure and change the way in which it is treated.
The way the technology works is to allow scientists to “train up” T cells, which fight cancer, within white blood cells, allowing them to kill tumours.
Chief executive of Scancell Dr Richard Goodfellow told the newspaper that the patent “significantly bolsters our global intellectual property portfolio as we position the company for future growth”.
The firm has also received similar patent protection in the US, Australia and Japan. It is already moving forwards with its first potential vaccine, designed to target melanoma.
SCIB1 is currently in early phase one and two human clinical trials, with the company reporting the results indicate a “highly encouraging survival trend without serious side effects”.
Of course, Scancell isn’t the only organisation using immunology to target cancer cells. Earlier this year the Daily Mail reported on a trial in Norway where a vaccine for prostate cancer showed promise in early phase 1 human clinical trials.
According to the newspaper, the injection was able to stop the cancer spreading in 77 per cent of the patients involved in the trial, with 45 per cent seeing their tumours shrink after receiving the vaccine.
If you need Absolute Ethanol 100 or other clinical supplies for your work in pharmaceuticals, contact our team today.